Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Kynmobi

(Apomorphine Injectable Solution)

SSamson Clinical Operations Pty Ltd

0

Indications

1

Total Trials

1

Active Trials

0

Competitors

3

FDA Applications

NDA/BLA/ANDA regulatory filings

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Parkinson Disease

NCT04957095

Clinical

Trials by Indication[1]

Parkinson disease1 trial

Motor Network Physiology Characterization During Deep Brain Stimulation Surgery

Recruiting·UUniversity of Texas Southwestern Medical Center·Preclinical·NCT04957095·120 enrolled

Regulatory

FDA Approval Timeline[3]

Apr 20, 2004

APOKYN

NDA NDA021264

May 21, 2020

KYNMOBI

NDA NDA210875

Feb 3, 2025

ONAPGO

NDA NDA214056

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Apomorphine Injectable Solution. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Apomorphine Injectable Solution compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (NDA NDA214056). U.S. Food & Drug Administration.
[4]
SEC EDGAR — Samson Clinical Operations Pty Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Company: SSamson Clinical Operations Pty Ltd

Related News